Feb. 14, 2025 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists, has published the TAILORED-AF clinical trial in Nature Medicine, which demonstrated that an AI-guided procedure for persistent atrial fibrillation (AF) in combination with conventional pulmonary vein isolation (PVI) treatment, resulted in better outcomes than PVI alone.

Feb. 12, 2025 — On Feb. 11, 2025, at HonorHealth Research Institute, Rahul Doshi, M.D., cardiac electrophysiologist, performed one of the nation’s first procedures to control atrial fibrillation (Afib) using a new type of catheter that can deliver two different types of electrical energy — or ablation — to destroy the damaged part of the heart that is triggering the abnormal heartbeats. It does this without harming any of the heart’s healthy tissue. Destroying the damaged tissue helps restore the heart’s regular rhythm.

Feb. 6, 2025 — Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announced publication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH).

The study, which was published in the Journal of the American Heart Association (JAHA), highlighted the algorithm’s ability to analyze heart sounds recorded with a digital stethoscope for identifying elevated pulmonary artery systolic pressures, a key indicator of PH.

Feb. 6, 2025 — New findings from the DiVERT Stroke clinical study showed women spent less time in the hospital, saw fewer referrals to cardiology, and were prescribed less frequent post-stroke cardiac monitoring than men when admitted to comprehensive stroke centers following stroke. The data were presented at the International Stroke Conference (ISC) in Los Angeles.

Feb. 5, 2025 — Removing a clot blocking a medium- or small-sized artery in the brain mechanically is a safe treatment for a common type of stroke; however, it did not lessen disability more than best medical treatment (including clot-busting medication if indicated) alone, according to preliminary late-breaking science presented at the American Stroke Association’s International Stroke Conference 2025 in Los Angeles.

Feb. 3, 2025 — Today, Peripheral Artery Disease (PAD) affects 10 million Americans and is the most common cause of limb amputation outside of trauma. Yet, 70 percent of Americans don’t know what it is or what signs to look for. 

During American Heart Month, the PAD Pulse Alliance, a coalition of four leading medical societies dedicated to improving vascular health, is raising awareness of PAD and providing resources for people to learn more about it. 

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 new customers with its ClearRead solutions to clearly, confidently and quickly detect cardiothoracic diseases.

January 29, 2025 – Roche announced today that the Tina-quant Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring lipoprotein (a), or Lp(a), in nanomoles per liter (nmol/L). The National Lipid Association (NLA) recommends all adults measure their Lp(a) – often referred to as L-P-Little-A – at least once in a lifetime to help assess cardiovascular risk.

Jan. 29, 2025 — Researchers at Ochsner Health, led by Hernan Bazan, MD, DFSVS, FACS, have developed a predictive model with a 93% accuracy rate in determining whether urgent carotid-intervention patients will regain functional independence. This study, “Precision in Stroke Care: A Novel Model for Predicting Functional Independence in Urgent Carotid Intervention Patients,” is now available in the Journal of the American College of Surgeons.  

Jan. 29, 2025 – Scandinavian Real Heart AB (recently aannounced that its total artificial heart, Realheart TAH, has been granted Humanitarian Use Device (HUD) designation by the U.S. Food and Drug Administration (FDA). The HUD designation makes Realheart TAH eligible to apply for Humanitarian Device Exemption (HDE), an expedited regulatory pathway that can grant the product limited marketing rights.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now